Targeting B7-H3 in Squamous Cell Carcinoma of the Head and Neck: Preclinical Proof-of-Concept with the Investigational Anti-B7-H3 Antibody-drug Conjugate, MGC018

Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

MacroGenics, Inc., Brisbane, CA and Rockville, MD

Presenting Contact Information: scribnerj@macrogenics.com

© 2021 MacroGenics, Inc. All rights reserved.

MGC018 Mediates Antitumor Activity Toward PDX Models of Head and Neck Cancer

Introduction

B7-H3: A Clinical-stage Anti-B7-H3 ADC Therapeutic

MGC018

MGC018 Mediates Apoptosis of FaDu SCCHN Tumor Cells

MGC018 Leads to Cell Cycle Arrest of FaDu SCCHN Tumor Cells

MGC018 Mediates Antitumor Activity Toward COX Models of SCCHN

PDX Model Characteristics

Results

B7-H3 is Overexpressed in SCCHN

B7-H3 Gene Expression in SCCHN Cell Lines (Relative to COX)

B7-H3 Tumor Expression and Heterogeneity is Generally Recaptured in PDX Models

B7-H3 in Squamous Cell Carcinoma of the Head and Neck: Preclinical Proof-of-Concept with the Investigational Anti-B7-H3 Antibody-drug Conjugate, MGC018

Head and Neck Cancer

- The targeting potential of MGC018 in patients will be evaluated in a phase 1b clinical trial

Conclusions

- B7-H3 is broadly expressed in SCCHN

- MGC018 mediated antitumor activity toward B7-H3-expressing SCCHN xenografts

- MGC018 demonstrates antitumor activity in vivo toward SCCHN xenografts

- MGC018 is a promising therapeutic for patients with SCCHN

References


Acknowledgements

- MGC018 is an investigational drug candidate in clinical development

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.

- Juniper A. Scribner, Francine Z. Chen, Ying Li, Michael Chiechi, Jeff Hooley, Thomas Son, Scott Koenig, Paul A. Moore, Ezio Bonvini, Chet Bohac, Deryk Loo

- MacroGenics, Inc., Brisbane, CA and Rockville, MD

- Presenting Contact Information: scribnerj@macrogenics.com

- © 2021 MacroGenics, Inc. All rights reserved.

- B7-H3 is an immunomodulatory molecule that is expressed in various tumor types

- MGC018 is a potent and selective targeting antibody against B7-H3

- MGC018 is a therapeutic antibody that mediates antitumor activity in vivo

- MGC018 is currently in clinical development for the treatment of head and neck cancer

- MGC018 is a promising therapeutic for patients with SCCHN

- © 2021 MacroGenics, Inc. All rights reserved.